Duff & Phelps Investment Management Co. reduced its position in Danaher Co. (NYSE:DHR - Free Report) by 8.8% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 52,782 shares of the conglomerate's stock after selling 5,116 shares during the period. Duff & Phelps Investment Management Co.'s holdings in Danaher were worth $14,674,000 at the end of the most recent quarter.
Other large investors have also modified their holdings of the company. LRI Investments LLC boosted its position in shares of Danaher by 82.5% in the 3rd quarter. LRI Investments LLC now owns 4,545 shares of the conglomerate's stock worth $1,264,000 after buying an additional 2,055 shares in the last quarter. Gordian Capital Singapore Pte Ltd increased its stake in Danaher by 26.1% during the third quarter. Gordian Capital Singapore Pte Ltd now owns 1,400 shares of the conglomerate's stock worth $389,000 after acquiring an additional 290 shares during the last quarter. PYA Waltman Capital LLC lifted its holdings in shares of Danaher by 3.0% during the 3rd quarter. PYA Waltman Capital LLC now owns 33,368 shares of the conglomerate's stock valued at $9,277,000 after acquiring an additional 970 shares in the last quarter. Geller Advisors LLC grew its stake in shares of Danaher by 3.7% in the third quarter. Geller Advisors LLC now owns 1,859 shares of the conglomerate's stock valued at $517,000 after buying an additional 67 shares in the last quarter. Finally, SGL Investment Advisors Inc. acquired a new stake in shares of Danaher during the third quarter valued at about $4,021,000. 79.05% of the stock is owned by institutional investors and hedge funds.
Danaher Stock Performance
Shares of DHR traded up $5.78 during trading hours on Monday, hitting $235.91. The stock had a trading volume of 2,625,253 shares, compared to its average volume of 2,779,061. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. Danaher Co. has a fifty-two week low of $217.96 and a fifty-two week high of $281.70. The firm has a 50-day moving average price of $250.76 and a 200 day moving average price of $258.32. The firm has a market capitalization of $170.39 billion, a price-to-earnings ratio of 43.92, a PEG ratio of 4.23 and a beta of 0.83.
Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating the consensus estimate of $1.57 by $0.14. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business's revenue for the quarter was up 3.1% compared to the same quarter last year. During the same quarter last year, the firm posted $2.02 earnings per share. As a group, research analysts anticipate that Danaher Co. will post 7.5 EPS for the current year.
Danaher Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.46%. The ex-dividend date was Friday, September 27th. Danaher's dividend payout ratio (DPR) is 20.61%.
Wall Street Analyst Weigh In
DHR has been the subject of a number of research reports. Barclays decreased their price objective on shares of Danaher from $285.00 to $275.00 and set an "equal weight" rating for the company in a report on Wednesday, October 23rd. Stephens reaffirmed an "overweight" rating and set a $315.00 price target on shares of Danaher in a research note on Wednesday, October 23rd. Robert W. Baird dropped their price target on Danaher from $278.00 to $277.00 and set an "outperform" rating on the stock in a report on Wednesday, October 23rd. StockNews.com cut Danaher from a "buy" rating to a "hold" rating in a research note on Thursday. Finally, KeyCorp increased their target price on shares of Danaher from $290.00 to $310.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, Danaher has an average rating of "Moderate Buy" and an average price target of $287.16.
Check Out Our Latest Analysis on DHR
Danaher Profile
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Further Reading
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
